Cantel Medical (CMD) Scheduled to Post Earnings on Thursday
Cantel Medical (NYSE:CMD) is set to post its quarterly earnings results before the market opens on Thursday, December 7th. Analysts expect Cantel Medical to post earnings of $0.52 per share for the quarter.
Cantel Medical (NYSE:CMD) last posted its quarterly earnings results on Thursday, September 28th. The company reported $0.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.02. The firm had revenue of $205.50 million for the quarter, compared to the consensus estimate of $200.32 million. Cantel Medical had a net margin of 9.27% and a return on equity of 17.60%. Cantel Medical’s quarterly revenue was up 14.8% on a year-over-year basis. On average, analysts expect Cantel Medical to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Cantel Medical (CMD) opened at $105.36 on Thursday. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.41 and a quick ratio of 1.49. The firm has a market cap of $4,449.50, a PE ratio of 51.01 and a beta of 1.23. Cantel Medical has a 52 week low of $69.21 and a 52 week high of $106.43.
In other Cantel Medical news, Director George L. Fotiades sold 6,000 shares of Cantel Medical stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $95.23, for a total transaction of $571,380.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Eric W. Nodiff sold 2,868 shares of Cantel Medical stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $97.55, for a total transaction of $279,773.40. Following the transaction, the executive vice president now directly owns 39,102 shares in the company, valued at $3,814,400.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 36,368 shares of company stock worth $3,576,028. Insiders own 14.90% of the company’s stock.
Several equities analysts have recently weighed in on the stock. Sidoti raised shares of Cantel Medical from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a research note on Wednesday, August 2nd. Zacks Investment Research raised shares of Cantel Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical in a research note on Friday, September 1st. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $91.67.
TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/30/cantel-medical-cmd-scheduled-to-post-earnings-on-thursday.html.
Cantel Medical Company Profile
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.